Skip to content

Use of Teicoplanin on a Three-weekly Administration in the Infectious Diseases Unit

Use of Teicoplanin on a Three-weekly Administration in the Complex Outpatient Macroactivity Regimen of Infectious Diseases Unit in the Alessandro Manzoni Hospital (Lecco, Italy)

Status
Recruiting
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT06426212
Acronym
3-TEICO
Enrollment
40
Registered
2024-05-23
Start date
2024-05-07
Completion date
2024-06-30
Last updated
2024-05-23

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Comparison of Teicoplanin Used Three Times a Week in DSIs vs NDISs

Brief summary

Teicoplanin is an antibiotic belonging to the class of glycopeptides, in use since 1986. Like its older classmate vancomycin, it inhibits protein synthesis by interfering with the synthesis of peptidoglycan, and is active on Gram-positive bacteria such as Staphilococcus spp (including MRSA), Streptococcus spp and Enterococcus spp (both faecalis and faecium). Teicoplanin is characterized by poor gastrointestinal absorption, which requires intramuscular or intravenous administration; has a binding to plasma proteins greater than 90%; and a high volume of distribution. It reaches high levels in deep tissues (bone, abdomen, lung, kidney, heart) on the contrary it has poor penetration at the central nervous system level; it is approved for the treatment of skin and soft tissue infections, osteo-articular infections, pneumonia, endocarditis, complicated urinary tract infections, peritonitis and bacteremia associated with the aforementioned clinical conditions. Furthermore, teicoplanin has a markedly long half-life (between 30 and 180h) which allows it to be administered even every 48-72h. Dose and duration of treatment should be adjusted according to the location and severity of the infection and based on patient characteristics such as renal function. The possibility of carrying out therapeutic drug monitoring (TDM) allows maintaining plasma levels adequate for the treatment of deep infections (e.g. \>20 mg/l for endocarditis) and avoiding overdose. Thanks to the possibility of administering teicoplanin on a three-weekly schedule, patient access to hospital is further reduced. The investigators therefore propose a retrospective study to evaluate the clinical effectiveness of teicoplanin therapy according to a three-weekly scheme by comparing its use in the treatment of deep infections (deep seated infections - DSIs) and superficial infections (non-deep seated infections - NDSIs).

Interventions

DRUGUse of teicoplanin three times a week

retrospective study to evaluate the clinical effectiveness of teicoplanin therapy according to a three-weekly scheme comparing its use in the treatment of deep infections (deep seated infections - DSIs) and superficial infections (non-deep seated infections - NDSIs).

Sponsors

Azienda Ospedaliera di Lecco
Lead SponsorOTHER

Study design

Observational model
CASE_ONLY
Time perspective
RETROSPECTIVE

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* Age \>18 years; * Patients with documented Gram-positive infection sensitive to teicoplanin; * Patients who have received at least 4 doses of teicoplanin on a three-weekly schedule, as monotherapy or associated with other antibiotics

Exclusion criteria

* Hospitalized patients * Patients who have received less than 4 doses of teicoplanin for any cause.

Design outcomes

Primary

MeasureTime frameDescription
Describe the clinical characteristics and outcome of the study population.2 monthsDescribe the clinical characteristics of patients and outcome (recovery vs therapeutic failure intended as death, need for modification of antibiotic therapy or recurrence of infection) of the study population.

Countries

Italy

Contacts

Primary ContactStefania Piconi, MD
s.piconi@asst-lecco.it+390341489890
Backup ContactSilvia Pontiggia, MS
s.pontiggia@asst-lecco.it+390341253678

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026